Study of HLX79 with Rituximab for Active Kidney Disease
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have primary membranous nephropathy (a specific kidney disease) diagnosed within the last 5 years, confirmed by a kidney biopsy or a positive blood test for anti-PLA2R antibodies.
- You have high levels of protein in your urine (more than 3.5 grams per day) or very high levels (over 8 grams per day).
- You have not used certain immunosuppressant drugs (like steroids, cyclophosphamide, or rituximab) in the past year, or if you used rituximab, your B cells have recovered.
- You do not have serious infections, unstable heart or lung conditions, or a history of cancer (except cured skin cancer).
- You agree to use effective birth control from when you sign up until 12 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications, rituximab and cyclosporine, for people with primary membranous nephropathy, a kidney disease that causes protein in the urine. The goal is to see if this combination can reduce protein loss and improve kidney function, potentially preserving kidney health.
This study tests a new drug called HSK39297 combined with standard treatments (steroids and mycophenolate mofetil) for people with active lupus nephritis. It aims to see if the combination is safe and effective in reducing kidney inflammation.
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
This study tests an experimental oral therapy called ADX-097 for people with three types of kidney disease: IgA nephropathy, lupus nephritis, or C3 glomerulopathy. The goal is to see if it’s safe and can help reduce kidney damage.
This trial tests if an artificial intelligence tool can help doctors decide the best dose and timing of rituximab for people with a kidney condition called membranous nephropathy. It aims to improve treatment results and reduce side effects.
This trial tests a new treatment for people with lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and protect kidney function.
Hear when a new Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.